Zenocutuzumab
Class
Targeted therapy
Subclass
Anti-HER2 / HER3 bispecific monoclonal antibodies
Substance name
Zenocutuzumab, zenocutuzumab-zbco
Brand names
Bizengri®
Common formulations
Solution for injection
Dosage and administration
Adults patients
Non-small cell lung cancer in patients with NRG1 fusion • Unresectable or metastatic, progression on or after prior systemic therapy
Pancreatic adenocarcinoma in patients with NRG1 fusion • Unresectable or metastatic, progression on or after prior systemic therapy
Indications for use
Labeled indications
Adults
Safety risks
Boxed warnings
Fetal toxicity
Warnings and precautions
ILD, pneumonitis
Infusion-related reactions, anaphylaxis
LV dysfunction
Specific populations
Renal impairment
CrCl ≥ 30 mL/min
CrCl < 30 mL/min
Renal replacement therapy
Any modality
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource